Cargando…

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis

BACKGROUND: Natalizumab is a highly effective monoclonal antibody for the treatment of multiple sclerosis (MS), which can diffuse in different anatomical compartments, including cerebrospinal fluid (CSF) and milk. OBJECTIVES: Starting from incidental detection of natalizumab in the CSF of MS patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Callegari, Ilaria, Schneider, Mika, Aebischer, Vera, Voortman, Margarete M., Proschmann, Undine, Ziemssen, Tjalf, Lindberg, Raija, Fischer-Barnicol, Bettina, Khalil, Michael, Kappos, Ludwig, Kuhle, Jens, Sanderson, Nicholas S.R., Derfuss, Tobias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896084/ https://www.ncbi.nlm.nih.gov/pubmed/36741352 http://dx.doi.org/10.1177/17562864221150040

Ejemplares similares

Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation
por: Proschmann, Undine, et al.
Publicado: (2021)

Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis
por: Proschmann, Undine, et al.
Publicado: (2021)

Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up
por: Kaufmann, Maxi, et al.
Publicado: (2018)

Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4(+) T Cells of Patients with Relapsing-Remitting Multiple Sclerosis
por: Meira, Maria, et al.
Publicado: (2014)

Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development
por: Meira, Maria, et al.
Publicado: (2016)

Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML
por: Fischer-Barnicol, Bettina, et al.
Publicado: (2020)

Hepatitis E virus infections in patients with MS on oral disease-modifying treatment
por: Diebold, Martin, et al.
Publicado: (2019)

Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects
por: Fischer, Stefanie, et al.
Publicado: (2021)

Should We Use Clinical Tools to Identify Disease Progression?
por: Inojosa, Hernan, et al.
Publicado: (2021)

The need for a strategic therapeutic approach: multiple sclerosis in check
por: Inojosa, Hernan, et al.
Publicado: (2022)

Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients
por: Kaufmann, Maxi, et al.
Publicado: (2018)

No Impact of Long-Term Fingolimod Treatment on Fecal Secretory Immunoglobulin A Levels in Patients With Multiple Sclerosis
por: Inojosa, Hernan, et al.
Publicado: (2020)

PARP-1 deregulation in multiple sclerosis
por: Meira, Maria, et al.
Publicado: (2019)

Can ChatGPT explain it? Use of artificial intelligence in multiple sclerosis communication
por: Inojosa, Hernan, et al.
Publicado: (2023)

Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS
por: Zimmermann, Maria, et al.
Publicado: (2015)

Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation
por: Thomas, Katja, et al.
Publicado: (2017)

Pilot study on the influence of acute alcohol exposure on biophysical parameters of leukocytes
por: Shalchi-Amirkhiz, Puya, et al.
Publicado: (2023)

Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificities
por: Rose, Natalie, et al.
Publicado: (2022)

Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype
por: Pröbstel, Anne-Katrin, et al.
Publicado: (2015)

Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS
por: Akgün, Katja, et al.
Publicado: (2019)

Influence of exercise on quantity and deformability of immune cells in multiple sclerosis
por: Proschmann, Undine, et al.
Publicado: (2023)

Influence of Pre-Analytic Conditions on Quantity of Lymphocytes
por: Proschmann, Undine, et al.
Publicado: (2023)

α4-integrin receptor desaturation and disease activity return after natalizumab cessation
por: Derfuss, Tobias, et al.
Publicado: (2017)

Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy
por: Rust, Heiko, et al.
Publicado: (2016)

New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies
por: Sehr, T., et al.
Publicado: (2016)

Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting
por: Rodriguez-Leal, Francisco Alejandro, et al.
Publicado: (2019)

Antigen Extraction and B Cell Activation Enable Identification of Rare Membrane Antigen Specific Human B Cells
por: Zimmermann, Maria, et al.
Publicado: (2019)

Gut microbiota composition as a candidate risk factor for dimethyl fumarate-induced lymphopenia in multiple sclerosis
por: Diebold, Martin, et al.
Publicado: (2022)

Immunological Predictors of Dimethyl Fumarate‐Induced Lymphopenia
por: Diebold, Martin, et al.
Publicado: (2022)

CNS inflammation after natalizumab therapy for multiple sclerosis: A retrospective histopathological and CSF cohort study
por: Häusler, Darius, et al.
Publicado: (2021)

Efficacy and Safety of Fingolimod in an Unselected Patient Population
por: Rasenack, Maria, et al.
Publicado: (2016)

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
por: Kappos, Ludwig, et al.
Publicado: (2015)

Differential effects of selective versus unselective sphingosine 1-phosphate receptor modulators on T- and B-cell response to SARS-CoV-2 vaccination
por: Proschmann, Undine, et al.
Publicado: (2023)

High-dimensional immune profiling identifies a biomarker to monitor dimethyl fumarate response in multiple sclerosis
por: Diebold, Martin, et al.
Publicado: (2022)

Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis
por: Ganapathy Subramanian, Ranjani, et al.
Publicado: (2021)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
por: Butzkueven, Helmut, et al.
Publicado: (2014)

Clinical effects of natalizumab on multiple sclerosis appear early in treatment course
por: Kappos, Ludwig, et al.
Publicado: (2013)

Breastmilk Cell and Fat Contents Respond Similarly to Removal of Breastmilk by the Infant
por: Hassiotou, Foteini, et al.
Publicado: (2013)

Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study
por: Butzkueven, Helmut, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_65uk12hmt3nnum84c9mbof5l9s